A novel stream of brain-penetrant HDAC6 inhibitors
Our R&D programme is focused on our next generation, brain-penetrant, non-hydroxamate, orally-available small molecules, which are being developed for the treatment of glioblastoma, and neurodegenerative and inflammatory disorders, where new biology is emerging.
Research focus
Lead Design | Lead Optimization | Pre-clinical Development | Phase I |
---|
Non-hydroxamate, brain-penetrant, HDAC6-targeted inhibitors
Clinical assets for partnering
Lead Design | Lead Optimization | Pre-clinical Development | Phase I |
---|